23 February 2021 | News
The 10,000 square foot lab, to be located in the Genome Valley, will accelerate and advance the local biopharma scale up needs
Cytiva, a global life science leader, and the State of Telangana in India will work together to open a new Fast Trak lab. The city of Hyderabad in Telangana, which has emerged as a leader in pharmaceuticals and biotechnology, is well-positioned to host such a facility. The 10,000 square foot lab, to be located in the Genome Valley, will accelerate and advance the local biopharma scale up needs.
The 10,000 square foot lab, to be located in the Genome Valley, will accelerate and advance the local biopharma scale up needs. With over 800 life sciences companies nearby, the new facility will help the area’s biotechnology hub increase production efficiency, reduce cost and speed to market.
India's biotechnology industry, estimated to reach 150 billion dollars by 2025, expects to see the number of emerging biotech companies boom from 3,475 to more than 10,000. The State of Telangana has a rich mix of global pharmaceutical companies, Indian local biopharma giants, and biotech startups. Combined, they contribute about 35% of India’s pharmaceutical production. Cytiva’s Fast Trak lab is ready to meet the area’s fast-growing demand.
Vaggu Raghavendra Goud, General Manager of Cytiva South Asia, says: “Cytiva has been growing alongside the Indian biotechnology industry for more than 30 years. A Fast Trak lab brings us closer to our customers in one of the world’s key biotechnology hubs. This partnership enables us to share our global knowledge and expertise at a regional level. It is a new milestone in our continued investment in the India market and another way we fully support the growth of the industry here.”
Shakti Nagappan, Director of Life Sciences and Pharma, the State Government of Telangana, says: “The government of Telangana has conceptualized Biopharma-Hub (B-Hub) as a Growth Phase Park to provide necessary support to young companies graduating from incubation stage along with this biopharma scale-up manufacturing facility of about 200L to help companies produce clinical material (phase 1 & 2). The scale-up facility will also provide training, which is a key requirement to facilitate the growth of biosimilars in the life sciences industry. We are happy to partner with Cytiva for this.”
With this collaboration with the State of Telangana, Cytiva continues its partnerships with the key players in the India biotechnology ecosystem. Together, they will work to address global demand and enable and accelerate industry development.